Search
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigational[A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. … The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Mixtures: Pal-pravastatin-asa, Pal-pravastatin-asaGlutethimide
go.drugbank.com/drugs/DB01437ApprovedIllicitIts use has been largely superseded by other drugs.
Minoxidil
go.drugbank.com/drugs/DB00350ApprovedInvestigationalA potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Products: Minoxidil Topical Solution USP, 2%, GOOD GUY Mens Hair Regrowth TreatmentPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.
Acemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigational[T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Hydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedHydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S.
Categories: Hormonal Contraceptives for Systemic UseRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies
Afatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalby an FDA-approved test [L2939]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.